We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
PerkinElmer Completes Acquisition of Antibody and Reagent Leader BioLegend
Product News

PerkinElmer Completes Acquisition of Antibody and Reagent Leader BioLegend

PerkinElmer Completes Acquisition of Antibody and Reagent Leader BioLegend
Product News

PerkinElmer Completes Acquisition of Antibody and Reagent Leader BioLegend

Credit: swiftsciencewriting/ Pixabay

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "PerkinElmer Completes Acquisition of Antibody and Reagent Leader BioLegend"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

PerkinElmer, Inc. (NYSE: PKI) has announced it has completed its acquisition of BioLegend, a leading, worldwide provider of life science antibodies and reagents for a total consideration of approximately $5.25 billion.

The acquisition, the largest in PerkinElmer’s history, further expands the Company’s life science franchise into high-growth areas such as cytometry, proteogenomics, multiplex assays, recombinant proteins, magnetic cell separation and bioprocessing.

Commenting on the collaboration ahead, Prahlad Singh, president and chief executive officer of PerkinElmer, said “BioLegend’s stellar leaders, teams and technologies will play a critical role in our combined companies’ ability to provide new, innovative solutions to scientists -- helping drive novel therapeutic discovery and development. We also look forward to BioLegend significantly enhancing our leading reagents portfolio as we partner together to innovate and advance science for our customers.”

Gene Lay, founder, president and chief executive officer of BioLegend, added “We are very excited to roll up our sleeves and work together with our new PerkinElmer colleagues to mutually leverage our portfolios, people and shared passion for innovation and science to accelerate the discovery and development of novel therapeutics. PerkinElmer’s broad life science platform and strong global infrastructure will help BioLegend continue to extend our mission of enabling our customers to do legendary discovery.”

Advertisement